Last updated: February 15, 2026
Overview of the drug
NDC 45963-0305 refers to Tazorac (tazarotene), a topical retinoid used for treatinig acne vulgaris, psoriasis, and other dermatological conditions. Tazorac is marketed by Vivus, Inc. and approved by the FDA since 1997. Its application landscape is mainly dermatology clinics, and it has a solid position in psoriasis management.
Market Size and Growth Drivers
- The global dermatology market is projected to reach approximately $24 billion by 2027, growing at a compound annual growth rate (CAGR) of 8.2% from 2020 to 2027[1].
- Tazarotene accounts for about 12% of topical retinoid prescriptions in the U.S., with a steady market share due to its efficacy and tolerability profile[2].
- Growing prevalence of acne (estimated 85 million Americans affected at some point, according to the American Academy of Dermatology[3]) and psoriasis (around 7.5 million Americans[4]) drives demand.
Key competitors
Top competitors include tretinoin (Retin-A), adapalene (Differin), and tazarotene. Launch of biosimilars or generics could affect Tazorac's market share.
Regulatory landscape
- No recent label updates or major regulatory barriers reported.
- Patent exclusivity expired in 2018, with generic versions introduced since[5].
- The exclusion of new indications could limit growth potential.
Price and Revenue Estimates
- Current average wholesale price (AWP) per 0.1% Tazorac cream (0.1% strength, 45g tube) hovers around $300–$350[6].
- Average retail price (after discounts and insurance adjustments) is approximately $200–$250 per tube.
- Annual revenue for Tazorac was roughly $150 million in 2022, representing about 5–6% of the total topical psoriasis segment[7].
Pricing trends
- Generic competition has exerted downward pressure since 2018, reducing list prices by approximately 20–25%.
- New formulations or combination products could alter pricing dynamics.
Future Price Projections (Next 3-5 Years)
| Year |
Price Range (per tube) |
Key Influences |
| 2023 |
$190 – $250 |
Continued generics presence, insurance negotiations |
| 2024 |
$180 – $240 |
Potential erosion of brand pricing, entry of biosimilar products (if approved) |
| 2025 |
$170 – $230 |
Market saturation, new competitors, patent expiry effects |
| 2026 |
$160 – $220 |
Increased competition, possibly heightened biosimilar activity |
| 2027 |
$150 – $210 |
Mature market with stable generic penetration |
Caveats
Pricing could stabilize or decrease further with increased generic penetration. Market disruptions (e.g., new drugs entering from pipeline or non-price factors) could alter projections.
Market Entry and Expansion Opportunities
- New formulations: Development of gels, sprays, or combination topical therapies could command premium pricing.
- Indications expansion: Securing approval for additional dermatologic conditions could expand the addressable market—however, no recent applications are in pipeline.
- Biosimilars and generics: Entry of biosimilar or bioequivalent generics may erode brand price premium but could also expand overall market volume.
Key Takeaways
- The drug faces significant generic competition which constrains pricing.
- Market size remains robust due to high prevalence rates of target conditions.
- Price projections foresee modest declines driven by continued generic penetration and market maturity.
- Opportunities lie in developing combination products or expanding indications, though none are currently active.
- Revenue stability depends on preserving prescriber preference and navigating reimbursement dynamics.
Frequently Asked Questions
1. What is the primary driver of Tazorac's market value?
Its efficacy in treating psoriasis and acne, coupled with prescriber loyalty, sustains its revenue amid increasing generic competition.
2. How does the price of Tazorac compare to its competitors?
Tazorac's list prices are slightly higher than adapalene but comparable to tretinoin, with generics significantly undercutting the branded product.
3. What are the key risks for future revenue growth?
Entry of biosimilars or generics, shifts in treatment paradigms, and changes in insurance reimbursement policies pose potential risks.
4. Are there opportunities for patent extensions or new formulations?
No recent patent extensions or reformulations have been announced, but future innovation could impact market dynamics.
5. How might market trends influence long-term pricing?
An increase in generic options and biosimilar entries will continue exerting downward pressure on prices over the next five years.
Citations
[1] MarketWatch, "Global Dermatology Market," 2022.
[2] IQVIA, Prescription Data, 2022.
[3] American Academy of Dermatology, "Acne Prevalence," 2021.
[4] CDC, Psoriasis Data, 2022.
[5] FDA, Patent and exclusivity status, 2018.
[6] GoodRx, Price Data, 2023.
[7] EvaluatePharma, Topical Dermatology Revenue, 2022.
